This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

doi:10.1111/obr.12841 Sargeant JA, Henson J, King JA, et al. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...